ulcerative colitis and semaglutide Based on current data, GLP-1s appear generally well tolerated in people with IBD, but we do not yet have large, long-term trials in people with UC, so I tell patients we should What are the considerations for

[DOI] [PubMed] [Google Scholar] 44.Lingvay I., Catarig A.M., Frias J.P., Kumar H., Lausvig N.L., le Roux C.W., Thielke D., Viljoen A., McCrimmon R.J

Starting at a lower dosesuch as PlexusDx's microdose GLP-1 protocol at $129/monthallows your digestive system to adapt gradually, potentially reducing gas-related symptoms

Semaglutide causes less severe gastroparesis than tirzepatide at equivalent doses, which may mean slightly less impact on oral medication absorption

The medication is available in 3 mg, 7 mg, and 14 mg tablets, with dosing typically initiated at the lowest strength and titrated upward based on glycemic response and tolerability

For those seeking even faster multi-pathway action, PlexusDx offers GLP-Squared (semaglutide plus tirzepatide), which activates both GLP-1 and GIP receptors simultaneously, potentially accelerating results for certain genetic profiles

BUT THIS MATTERS BECAUSE WHAT WE SAW IN THE ADULT SIDE OF THINGS IS THAT AND ACTUALLY, YOU KNOW, WITH PEDIATRIC TRIALS TOO, IS THAT OFTEN WHAT HAPPENED IS THE INDICATION FOR TYPE TWO DIABETES CAME FIRST WITH APPROVAL FROM THE FDA